{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:50:45Z","timestamp":1790787045208,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The simultaneous occurrence of severe atopic dermatitis (AD), vitiligo, and alopecia areata (AA) in a single patient is exceptionally rare and poses a significant therapeutic challenge, as conventional \u201cdisease-specific\u201d therapies often yield suboptimal results. Emerging evidence implicates the shared JAK-STAT signaling pathway in the pathogenesis of these conditions, suggesting the potential for a targeted \u201cmulti-disease therapy\u201d approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 57-year-old man presented with severe, treatment-refractory AD, extensive vitiligo, and AA. Following the failure of conventional therapies, treatment with the selective JAK1 inhibitor upadacitinib (15 mg daily) was initiated. A rapid and marked improvement was observed: pruritus subsided within days, AD-related erythema cleared substantially by 15 weeks, complete eyebrow regrowth occurred within months, and significant repigmentation of vitiligo lesions was evident at one-year follow-up. The treatment was well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that upadacitinib monotherapy may be an effective and well-tolerated option for severe co-existing AD, vitiligo, and AA. It provides clinical evidence supporting the novel \u201cmulti-disease therapy\u201d paradigm, which targets common pathogenic pathways rather than individual disease phenotypes, offering a new strategic direction for managing complex immune-mediated comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1795986","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:31Z","timestamp":1780896991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mianyang 404 Hospital","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.04.016","article-title":"Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata","volume":"156","author":"Tordjman","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02875-0","article-title":"Epidemiology and treatment patterns of patients with vitiligo: A real-world analysis","volume":"41","author":"Ramot","year":"2024","journal-title":"Adv Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0114","article-title":"Bilateral association between atopic dermatitis? and alopecia areata: A systematic review and meta-analysis","volume":"35","author":"Sun","year":"2024","journal-title":"Dermatitis: Contact Atopic Occupational Drug"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1277179","article-title":"Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature","volume":"28","author":"Samadi","year":"2017","journal-title":"J Dermatol Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.019","article-title":"Emerging therapies for atopic dermatitis: JAK inhibitors","volume":"78","author":"Cotter","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.abd.2024.06.001","article-title":"Update on the pathogenesis of atopic dermatitis","volume":"99","author":"Criado","year":"2024","journal-title":"Bras Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111029","article-title":"Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment","volume":"124","author":"Shih","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","article-title":"Janus kinase inhibitors for alopecia areata: A review of clinical data","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3685","article-title":"Inhibiting Janus kinases to treat alopecia areata","volume":"20","author":"Divito","year":"2014","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cytogfr.2024.11.002","article-title":"JAK inhibitors in immune regulation and treatment of vitiligo","volume":"80","author":"Liu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.043","article-title":"Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation","volume":"78","author":"Whitlock","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1836313","article-title":"Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: A systematic review","volume":"33","author":"Conforti","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82887","article-title":"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda","year":"2016","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.12.28","article-title":"Therapeutic effects of upadacitinib on experimental autoimmune uveitis: Insights from single-cell analysis","volume":"64","author":"Huang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000544868","article-title":"Upadacitinib for alopecia: Current evidence and clinical insights","volume":"11","author":"Stirrat","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00975-3","article-title":"Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: Phase 3 randomized clinical trial results through 140 weeks","volume":"26","author":"Irvine","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf138","article-title":"Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study","volume":"19","author":"Loftus","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00842-7","article-title":"Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the Phase 3 Rising Up study","volume":"13","author":"Katoh","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01373-7","article-title":"Early achievement of high treatment targets in moderate-to-severe atopic dermatitis with upadacitinib: Real-world evidence from the observational UP-TAINED study","volume":"15","author":"Weidinger","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.11.064","article-title":"Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2","volume":"94","author":"Senna","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: Insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","article-title":"JAK inhibitors for the treatment of vitiligo","volume":"113","author":"Inoue","year":"2024","journal-title":"J Dermatol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040521","article-title":"Melanin biopolymers in pharmacology and medicine-skin pigmentation disorders, implications for drug action, adverse effects and therapy","volume":"17","author":"Karkoszka","year":"2024","journal-title":"Pharm (Basel Switzerland)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-025-02230-y","article-title":"microRNA-34 mediates a negative feedback loop in the JAK-STAT pathway to attenuate immune overactivation in an invertebrate","volume":"23","author":"Zuo","year":"2025","journal-title":"Cell Communication Signaling: CCS"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-014-2101-8","article-title":"SCF\/c-kit signaling is required in 12-O-tetradecanoylphorbol-13-acetate-induced migration and differentiation of hair follicle melanocytes for epidermal pigmentation","volume":"360","author":"Qiu","year":"2015","journal-title":"Cell Tissue Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13931","article-title":"Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: Report of a case and review of the literature","volume":"57","author":"Di Tullio","year":"2018","journal-title":"Int J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: Update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf131","article-title":"Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-centre retrospective study","volume":"50","author":"Ji","year":"2025","journal-title":"Clin Exp Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:32Z","timestamp":1780896992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1795986"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1795986","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1795986"}}